返回 Agenda
Session Chair(s)
Steve Hughes, MD
Vice President, Clinical Development
Isis Pharmaceuticals, Inc., United States
Yang-min (Max) Ning
Medical Officer, Division of Oncology Products, OND/OHOP/CDER
FDA, United States
Speaker(s)
Development of MRX34, the First microRNA Mimic in the Clinic
Sinil Kim, MD
Mirna Therapeutics, United States
Chief Medical Officer
Development of Next Generation Anti-sense Molecules for Therapeutic Utility in Oncology
David Blakey, PHD
AstraZeneca, United Kingdom
Chief Scientist, Oncology
Tekmira
Ian MacLachlan, PHD
Tekmira Pharmaceuticals Corporation, Canada
Executive Vice President and Chief Scientific Officer